<DOC>
	<DOCNO>NCT00476853</DOCNO>
	<brief_summary>A 48 week , randomize , open-label , two arm study compare efficacy , safety tolerability HAART contain nevirapine 400 mg/day versus nevirapine 600 mg/day HIV-1 infect patient start 2-6 week initiate rifampicin contain antituberculosis therapy .</brief_summary>
	<brief_title>Efficacy Safety Study Comparing 2 Doses NVP After Initiating Rifampin-containing TB Therapy</brief_title>
	<detailed_description>Preliminary data HIVNAT PK laboratory indicate 5/60 patient treated nevirapine ( 200 mg bid ) rifampicin sub-therapeutic nevirapine level ( &lt; 3.0 mg mg/L ) . In control group 38 patient use nevirapine without rifampicin sub-therapeutic level . A dose increase nevirapine patient receive rifampicin may require . Both nevirapine rifampicin tepatotoxic agent agent use treatment HIV tuberculosis . Using high nevirapine may prevent occurrence sub-therapeutic nevirapine level , may also induce liver toxicity . To address issue , design randomize prospective study evaluate safety , efficacy pharmacokinetics nevirapine 400 mg/day versus 600 mg/day two week lead-in 200 mg/day 400 mg/day respectively , TB-HIV co-infected patient take rifampicin short-term efficacy toxicity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . Confirmed HIV positive voluntary counseling test 2 . Aged 1860 year age 3 . Antiretroviral treatment na√Øve . 4 . CD4+ cell count &lt; 200 cells/mm3 time diagnose TB 5 . TB diagnose use treatment rifampin base therapy least 2 week longer 4 week duration . The requirement study entry least one acidfast bacillus ( AFB ) positive smear typical syndrome and/or CXR finding consistent pulmonary TB . Pulmonary TB / extra pulmonary TB include AFB culture TB positive . 6 . No active OI ( CDC class C event ) 7 . Negative pregnancy test female , willing use reliable contraception 8 . Able provide write informed consent . 1 . The following laboratory variable , i. absolute neutrophil count ( ANC ) &lt; 1000 cells/uL ii . hemoglobin &lt; 6.5 g/dL iii . platelet count &lt; 50,000 cells/uL iv . serum AST , ALT &gt; 5 x ULN vi . serum bilirubin &gt; 2 x ULN vii . serum creatinine &gt; 2 x ULN viii . Pregnant nursing mother . 2 . Current use steroid immunosuppressive agent . 3 . Current use prohibit medication related compliance drug pharmacokinetics ( see appendix ) 4 . Acute therapy serious infection serious medical illness ( judgment site Principal Investigator ) require systemic treatment and/or hospitalization . 5 . Patients current alcohol illicit substance use opinion site Principal Investigator would conflict aspect conduct trial . 6 . The person receive monotherapy nevirapine 7 . Unlikely able remain followup protocol define period . 8 . Patients chronic active liver disease . 9 . Patients proven suspect acute hepatitis . Patients chronic viral hepatitis eligible provide ALT , AST &lt; 5 x ULN . 10 . Karnofsky performance score &lt; 30 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HIV-TB</keyword>
	<keyword>nevirapine base HAART rifampin treat TB</keyword>
	<keyword>Compare PK profile , efficacy , safety tolerability HAART contain nevirapine 400mg/day versus 600 mg/day HIV/TB co-infected patient</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>